Avalo Therapeutics (AVTX) Fundamental Analysis: Revenue, Earnings & Valuation

4.45 / 10

Netural

The security demonstrates mixed fundamental health (4.5/10). Positive indicators: Interest coverage ratio (EBIT / Interest expense) (%) and PB-ROE, however risks emerge in Asset-MV and Fixed assets turnover ratio. Analytical conclusion: defensive.

Analysis Checks(8/10)

Revenue-MV

Value-6.40

Score3/3

Weight50.70%

1M Return7.95%

Total operating revenue (YoY growth rate %)

Value-86.62

Score2/3

Weight2.04%

1M Return0.41%

Inventory turnover ratio

Value98.02

Score2/3

Weight-5.31%

1M Return-1.19%

Profit-MV

Value0.62

Score2/3

Weight22.13%

1M Return4.10%

PB-ROE

Value0.61

Score2/3

Weight24.41%

1M Return4.39%

Fixed assets turnover ratio

Value0.07

Score1/3

Weight-7.69%

1M Return-1.72%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-4.93%

1M Return-1.07%

Operating revenue (YoY growth rate %)

Value-86.62

Score2/3

Weight3.40%

1M Return0.68%

Cost of sales ratio (%)

Value71.86

Score2/3

Weight-6.18%

1M Return-1.40%

Asset-MV

Value-0.72

Score1/3

Weight21.44%

1M Return3.90%

Is AVTX undervalued or overvalued?

AVTX scores 4.45/10 on fundamentals and holds a Fair valuation at present. Backed by its -72.43% ROE, -132642.37% net margin, -5.17 P/E ratio, 4.87 P/B ratio, and 26.45% earnings growth, these metrics solidify its Netural investment rating.